Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproate

B. Melegh, J. Kerner, V. Jaszai, L. L. Bieber

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The fate of supplemental carnitine was studied in human subjects treated with drugs known to cause carnitine deficiency. Six children were treated with pivampicillin and equimolar l-carnitine for 7 days. On the last day of treatment, the plasma levels of total and free carnitine were decreased, but acylcarnitine levels were increased. A 12-fold increase in urinary excretion of acylcarnitines was found; it increased from 188.5 ± 82.7 to 2218.4 ± 484.1 μmole/day, and 84% was pivaloylcarnitine. Free carnitine excretion was reduced. Ten epileptic children on chronic valproate treatment received equimolar carnitine for a 2-week period. Plasma carnitine levels were elevated on the last day of treatment. A 3.4-fold increase in urinary acylcarnitines was found, but most of the excreted carnitines were free (64.5-fold increases). These data show that pivalate is readily converted to carnitine esters, in contrast to the limited conversion of valproate to acylcarnitines in humans.

Original languageEnglish
Pages (from-to)30-38
Number of pages9
JournalBiochemical Medicine and Metabolic Biology
Volume43
Issue number1
DOIs
Publication statusPublished - 1990

Fingerprint

Pivampicillin
Carnitine
Valproic Acid
Xenobiotics
Esters
Plasmas
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproate. / Melegh, B.; Kerner, J.; Jaszai, V.; Bieber, L. L.

In: Biochemical Medicine and Metabolic Biology, Vol. 43, No. 1, 1990, p. 30-38.

Research output: Contribution to journalArticle

@article{99ab74942f834733a8d8727da70d7ef5,
title = "Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproate",
abstract = "The fate of supplemental carnitine was studied in human subjects treated with drugs known to cause carnitine deficiency. Six children were treated with pivampicillin and equimolar l-carnitine for 7 days. On the last day of treatment, the plasma levels of total and free carnitine were decreased, but acylcarnitine levels were increased. A 12-fold increase in urinary excretion of acylcarnitines was found; it increased from 188.5 ± 82.7 to 2218.4 ± 484.1 μmole/day, and 84{\%} was pivaloylcarnitine. Free carnitine excretion was reduced. Ten epileptic children on chronic valproate treatment received equimolar carnitine for a 2-week period. Plasma carnitine levels were elevated on the last day of treatment. A 3.4-fold increase in urinary acylcarnitines was found, but most of the excreted carnitines were free (64.5-fold increases). These data show that pivalate is readily converted to carnitine esters, in contrast to the limited conversion of valproate to acylcarnitines in humans.",
author = "B. Melegh and J. Kerner and V. Jaszai and Bieber, {L. L.}",
year = "1990",
doi = "10.1016/0885-4505(90)90005-L",
language = "English",
volume = "43",
pages = "30--38",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproate

AU - Melegh, B.

AU - Kerner, J.

AU - Jaszai, V.

AU - Bieber, L. L.

PY - 1990

Y1 - 1990

N2 - The fate of supplemental carnitine was studied in human subjects treated with drugs known to cause carnitine deficiency. Six children were treated with pivampicillin and equimolar l-carnitine for 7 days. On the last day of treatment, the plasma levels of total and free carnitine were decreased, but acylcarnitine levels were increased. A 12-fold increase in urinary excretion of acylcarnitines was found; it increased from 188.5 ± 82.7 to 2218.4 ± 484.1 μmole/day, and 84% was pivaloylcarnitine. Free carnitine excretion was reduced. Ten epileptic children on chronic valproate treatment received equimolar carnitine for a 2-week period. Plasma carnitine levels were elevated on the last day of treatment. A 3.4-fold increase in urinary acylcarnitines was found, but most of the excreted carnitines were free (64.5-fold increases). These data show that pivalate is readily converted to carnitine esters, in contrast to the limited conversion of valproate to acylcarnitines in humans.

AB - The fate of supplemental carnitine was studied in human subjects treated with drugs known to cause carnitine deficiency. Six children were treated with pivampicillin and equimolar l-carnitine for 7 days. On the last day of treatment, the plasma levels of total and free carnitine were decreased, but acylcarnitine levels were increased. A 12-fold increase in urinary excretion of acylcarnitines was found; it increased from 188.5 ± 82.7 to 2218.4 ± 484.1 μmole/day, and 84% was pivaloylcarnitine. Free carnitine excretion was reduced. Ten epileptic children on chronic valproate treatment received equimolar carnitine for a 2-week period. Plasma carnitine levels were elevated on the last day of treatment. A 3.4-fold increase in urinary acylcarnitines was found, but most of the excreted carnitines were free (64.5-fold increases). These data show that pivalate is readily converted to carnitine esters, in contrast to the limited conversion of valproate to acylcarnitines in humans.

UR - http://www.scopus.com/inward/record.url?scp=0025259120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025259120&partnerID=8YFLogxK

U2 - 10.1016/0885-4505(90)90005-L

DO - 10.1016/0885-4505(90)90005-L

M3 - Article

C2 - 2106908

AN - SCOPUS:0025259120

VL - 43

SP - 30

EP - 38

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1

ER -